Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Background: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure. Methods: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and Singapore. Eligible patients were aged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (defined as ferritin

Detaljer

Författare
  • AFFIRM-AHF investigators
  • Piotr Ponikowski
  • Marcus Ohlsson
  • Ewa A. Jankowska
Enheter & grupper
Externa organisationer
  • Wroclaw Medical Hospital
  • Wrocław Medical University
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi
Originalspråkengelska
Sidor (från-till)1895-1904
TidskriftThe Lancet
Volym396
Utgåva nummer10200
StatusPublished - 2020
PublikationskategoriForskning
Peer review utfördJa